Oral Resveratrol to Prevent Post-ERCP Pancreatitis
Status:
Unknown status
Trial end date:
2018-09-01
Target enrollment:
Participant gender:
Summary
Acute pancreatitis is the most common and feared complication of ERCP, occurring after 1% to
30% of procedures. Since 2012, a multicenter RCT was published in NEJM, indomethacin use in
high risk patients was considered a "standard" method to prevent PEP. However, the risk
factors of PEP is not fully clear. Additionally, the complication of NSAID use lead to some
serious physical problem bleeding. Therefore, the exclusive criteria for limiting the NSAID
use is including allergy， gastrointestinal haemorrhage ，presence of coagulopathy or received
anticoagulation therapy. Previous study showed that another natural compound, resveratrol,
owns similar biological effect with NSAID. Firstly, it could inhibit the inflammatory
response on in vivo model through inhibition of COX and IL-6 etc. Secondly, it could not
influence the level of platelet and coagulation, which means safer than NSAID. Thirdly,
numerous studies showed that resveratrol could effectively the progression of severe acute
pancreatitis. According to data, we design the project. The purpose of this study is to
determine whether oral resveratrol pre-ERCP is effective on control of Post-ERCP
pancreatitis.
Phase:
Phase 4
Details
Lead Sponsor:
First Affiliated Hospital Xi'an Jiaotong University